Viking Therapeutics, Inc. (NASDAQ:VKTX) shares were up 6.2% on Friday . The company traded as high as $1.17 and last traded at $1.19. Approximately 736,537 shares traded hands during trading, an increase of 243% from the average daily volume of 214,594 shares. The stock had previously closed at $1.12.

A number of research analysts have weighed in on VKTX shares. Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of Viking Therapeutics in a research report on Thursday, May 11th. ValuEngine lowered shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 target price (up previously from $5.00) on shares of Viking Therapeutics in a research report on Monday, July 17th.

The firm has a 50-day moving average price of $1.05 and a 200-day moving average price of $1.22. The stock’s market capitalization is $31.85 million.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. On average, equities research analysts expect that Viking Therapeutics, Inc. will post ($0.82) earnings per share for the current year.

A hedge fund recently bought a new stake in Viking Therapeutics stock. Virtu KCG Holdings LLC bought a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 114,507 shares of the biotechnology company’s stock, valued at approximately $124,000. Virtu KCG Holdings LLC owned approximately 0.48% of Viking Therapeutics at the end of the most recent reporting period. Institutional investors own 5.67% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Viking Therapeutics, Inc. (VKTX) Trading Up 6.2%” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.